Noramco
Noramco
Noramco
  • About Us
    • About Noramco
    • Our People
    • Leadership
    • Excellence in Compliance
    • Minimizing Risk
  • Products & Solutions
    • Active Pharmaceutical Ingredients
      • Active Pharmaceutical Ingredients
      • Nal Family of Antagonists
      • ADHD / Stimulants
      • Full Product List
    • Noramco Solutions
      • Noramco Solutions
      • Clinical Supply
      • Controlled Substance Building Blocks and Intermediates
    • Platform Technologies
      • Platform Technologies
      • Platform Technology: Custom Synthesis
    • Reference Standards
      • Reference Standards
      • Reference Standards: Custom Synthesis
    • Reference Standards Store
  • Careers
  • News & Events
    • News & Events
    • Press Releases
  • Contact

Sort by

  • Default sorting
  • Sort by popularity
  • Sort by newness
  • Sort by price: low to high
  • Sort by price: high to low

View

  • 9 items
  • 15 items
  • 30 items

Showing 1–9 of 15 results

  • 135_10-Hydroxynaltrexone-Base
    Quick ViewSelect options

    10-Hydroxynaltrexone Base (CII)

    $1,438.00 – $5,752.00
    <span style="color: #000000;"><strong>CAS#</strong></span> 60767-82-0 <span style="color: #000000;"><strong>NDC#</strong></span> 51634-2052-**
    Quick ViewSelect options
  • 136_10-Ketonaltrexone-Base
    Quick ViewSelect options

    10-Ketonaltrexone Base (CII)

    $1,438.00 – $5,752.00
    <span style="color: #000000;"><strong>OTHER NAMES:</strong></span> EP Impurity I <span style="color: #000000;"><strong>CAS#</strong></span> 96445-14-6 <strong><span style="color: #000000;">NDC#</span></strong> 51634-2011-**
    Quick ViewSelect options
  • 137_14-Hydroxy-17-cyclopropylmethylnormorphinone-Base
    Quick ViewSelect options

    14-Hydroxy-17-cyclopropylmethylnormorphinone Base (CII)

    $719.00 – $2,876.00
    <span style="color: #000000;"><strong>CAS#</strong></span> 123086-68-0 <span style="color: #000000;"><strong>NDC#</strong></span> 51634-2012-**
    Quick ViewSelect options
  • 138_2,2'-Bisnaltrexone-Base
    Quick ViewSelect options

    2,2′-Bisnaltrexone Base (CII)

    $1,438.00 – $5,752.00
    <span style="color: #000000;"><strong>OTHER NAMES:</strong></span> EP Impurity D; Pseudonaltrexone <span style="color: #000000;"><strong>CAS#</strong></span> 607732-61-6 <span style="color: #000000;"><strong>NDC#</strong></span> 51634-1061-**
    Quick ViewSelect options
  • 139_3-(Cyclopropylmethyl)-Naltrexone-Base
    Quick ViewSelect options

    3-(Cyclopropylmethyl) Naltrexone Base (CII)

    $575.00 – $2,300.00
    <span style="color: #000000;"><strong>OTHER NAMES:</strong></span> EP Impurity E <span style="color: #000000;"><strong>CAS#</strong></span> 767615-69-0 <span style="color: #000000;"><strong>NDC#</strong></span> 51634-1062-**
    Quick ViewSelect options
  • 140_3-O-Methylnaltrexone-Base
    Quick ViewSelect options

    3-O-Methylnaltrexone Base (CII)

    $719.00 – $2,876.00
    <span style="color: #000000;"><strong>OTHER NAMES:</strong></span> 3-O-Methylnaltrexone Base (CII) <span style="color: #000000;"><strong>CAS#</strong> </span>16617-07-5 <span style="color: #000000;"><strong>NDC#</strong></span> 51634-2104-**
    Quick ViewSelect options
  • 141_8-Hydroxynaltrexone-Base
    Quick ViewSelect options

    8-Hydroxynaltrexone Base (CII)

    $719.00 – $2,876.00
    <span style="color: #000000;"><strong>NDC#</strong></span> 51634-2007-**
    Quick ViewSelect options
  • 142_N-(3-Butenyl)-noroxymorphone-Base
    Quick ViewSelect options

    N-(3-Butenyl)-noroxymorphone Base (CII)

    $575.00 – $2,300.00
    <span style="color: #000000;"><strong>OTHER NAMES:</strong></span> USP Compound A; EP Impurity C <span style="color: #000000;"><strong>CAS#</strong></span> 189016-90-8 <span style="color: #000000;"><strong>NDC#</strong></span> 51634-2013-**
    Quick ViewSelect options
  • 143_Naltrexone-Aldol-Dimer-Base
    Quick ViewSelect options

    Naltrexone Aldol Dimer Base (CII)

    $1,438.00 – $5,752.00
    <span style="color: #000000;"><strong>CAS#</strong></span> 607732-61-6 <span style="color: #000000;"><strong>NDC#</strong></span> 51634-1063-**
    Quick ViewSelect options
  • 1
  • 2

Recent Articles

  • Noramco CEO Lee Karras discusses $25 million Halo investment with PharmTech
  • Diversifying the Supply of Raw Materials
  • Noramco Announces Strategic Alignment with Purisys and Halo Pharma, Launching the Noramco Group as an Integrated North American-Based API and Drug Product Supply Chain Services Provider
  • Noramco Announces the Acquisition of the Cambrex Drug Product Business Unit
  • Noramco Announces Submission and Reactivation of the Drug Master File for Active Pharmaceutical Ingredient Methylnaltrexone Bromide
Copyright 2025 Noramco. All Rights Reserved. Contact | Legal Notice | Privacy Policy | Terms & Conditions | Benefits Transparency Mandate